Brokers Set Expectations for BioVie Q3 Earnings

BioVie Inc. (NASDAQ:BIVI) – Equities researchers at Brookline Capital Management issued their Q3 2025 earnings per share (EPS) estimates for shares of BioVie in a note issued to investors on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian anticipates that the company will earn ($0.32) per share for the quarter. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. Brookline Capital Management also issued estimates for BioVie’s Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($1.63) EPS.

BioVie Price Performance

NASDAQ BIVI opened at $1.12 on Friday. The firm has a market cap of $20.67 million, a PE ratio of -0.11 and a beta of 0.51. BioVie has a one year low of $0.99 and a one year high of $7.50. The stock’s 50 day simple moving average is $1.60 and its 200 day simple moving average is $2.12.

BioVie (NASDAQ:BIVI) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.46) EPS for the quarter.

Institutional Investors Weigh In On BioVie

A number of large investors have recently bought and sold shares of BIVI. Millennium Management LLC bought a new stake in BioVie during the 4th quarter worth approximately $245,000. Geode Capital Management LLC grew its position in BioVie by 223.3% during the 4th quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock worth $247,000 after acquiring an additional 85,234 shares during the last quarter. Drive Wealth Management LLC bought a new position in BioVie in the 4th quarter worth approximately $120,000. Bank of Montreal Can bought a new position in BioVie in the 4th quarter worth approximately $100,000. Finally, Sanders Morris Harris LLC acquired a new position in BioVie during the 4th quarter worth $85,000. 4.59% of the stock is currently owned by institutional investors.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.